Residency · Residency · Internal Medicine

Drug Allergy Assessment and Penicillin Allergy De-labeling

Introduction

Approximately 10-15% of hospitalized patients report a drug allergy, with penicillin being the most commonly reported. However, over 90% of patients labeled as penicillin-allergic are not truly allergic when formally tested. Inappropriate allergy labels lead to the use of broader-spectrum, more expensive, and often less effective antibiotics, driving antimicrobial resistance and increasing adverse events.

Drug Allergy Classification

Immune-Mediated Reactions (Gell and Coombs)

• Type I (Immediate/IgE-mediated): urticaria, angioedema, bronchospasm, anaphylaxis; occurs within 1-6 hours
• Type II (Cytotoxic): drug-induced cytopenias (e.g., hemolytic anemia from cephalosporins)
• Type III (Immune complex): serum sickness, drug-induced vasculitis; occurs 1-3 weeks after exposure
• Type IV (Delayed/T-cell-mediated): maculopapular rash, contact dermatitis, SJS/TEN, DRESS; occurs 24 hours to weeks later

Non-Immune Reactions

• Drug intolerance: GI upset, headache (not a true allergy)
• Drug side effects: predictable pharmacologic effects (e.g., diarrhea with amoxicillin)
• Non-allergic drug hypersensitivity: vancomycin-associated Red Man Syndrome (histamine-mediated, not IgE)

Taking a Thorough Drug Allergy History

• What was the reaction? Specific symptoms (rash, swelling, breathing difficulty, GI upset)
• When did it occur? Timing relative to drug administration
• How long ago? IgE-mediated sensitivity wanes over time (80% lose sensitivity within 10 years)
• Was treatment required? Epinephrine, hospitalization, ICU admission
• Has the drug been tolerated since? If tolerated subsequently, allergy is effectively ruled out
• What was the indication? Viral illness with rash may have been misattributed

Penicillin Allergy: The Scope of the Problem

• Penicillin allergy is documented in 10% of the US population
• Patients with penicillin allergy labels receive more vancomycin, fluoroquinolones, and carbapenems
• This leads to increased rates of C. difficile infection, MRSA, VRE, and antimicrobial resistance
• Penicillin allergy labels are associated with longer hospital stays, higher costs, and worse surgical site infection rates
• Cross-reactivity between penicillins and cephalosporins is approximately 1-2% (much lower than historically cited 10%)

Penicillin Allergy De-labeling Strategies

Risk Stratification

• Low risk: remote childhood rash, isolated GI symptoms, family history only, unknown reaction > 10 years ago
• Moderate risk: urticaria, pruritic rash occurring within hours of administration
• High risk: anaphylaxis, angioedema, bronchospasm, or severe cutaneous reactions (SJS/TEN, DRESS, AGEP)

Testing and Challenge Approaches

• Direct oral challenge (amoxicillin): appropriate for low-risk patients; give supervised dose and observe for 1-2 hours
• Penicillin skin testing: uses major determinant (penicilloyl-polylysine/Pre-Pen) and minor determinants; 97-99% negative predictive value
• Graded dose challenge: for moderate-risk patients after negative skin testing
• Patients with history of SJS/TEN, DRESS, or AGEP should never be re-challenged with the offending drug

Implementation in Clinical Practice

• Antibiotic stewardship programs should integrate penicillin allergy assessment
• Pharmacist-led and nurse-driven protocols for allergy interviews and low-risk direct challenges are effective
• Electronic health record alerts can identify candidates for de-labeling
• After successful challenge, update the allergy record and educate the patient

Cross-Reactivity Between Beta-Lactams

• Penicillin-cephalosporin cross-reactivity is 1-2%, primarily driven by similar R1 side chains
• Cephalosporins with dissimilar side chains (e.g., ceftriaxone, cefepime) have negligible cross-reactivity with amoxicillin/ampicillin
• Carbapenems have < 1% cross-reactivity with penicillins and can generally be administered safely
• Aztreonam has no cross-reactivity with penicillins (except with ceftazidime, which shares an identical side chain)

Severe Drug Reactions Requiring Permanent Avoidance

• Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN): life-threatening desquamation; avoid the drug class permanently
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): multi-organ involvement; 10% mortality
• Acute Generalized Exanthematous Pustulosis (AGEP): widespread sterile pustules
• Drug-induced anaphylaxis with confirmed testing: maintain allergy label with clear documentation

Key Clinical Pearls

• Over 90% of patients labeled penicillin-allergic can safely receive penicillins after formal evaluation.
• A detailed allergy history is the most important first step and can often risk-stratify without skin testing.
• Low-risk patients can undergo direct oral amoxicillin challenge without prior skin testing.
• True penicillin-cephalosporin cross-reactivity is approximately 1-2%, not the historical 10%.
• Never re-challenge patients with a history of SJS/TEN, DRESS, or AGEP to the implicated drug.

References

1. Shenoy ES, Macy E, Rowe T, et al. Evaluation and Management of Penicillin Allergy: A Review. JAMA. 2019;321(2):188-199.
2. Blumenthal KG, Peter JG, Trubiano JA, et al. Antibiotic Allergy. The Lancet. 2019;393(10167):183-198.
3. Macy E, Contreras R. Health Care Use and Serious Infection Prevalence Associated with Penicillin "Allergy" in Hospitalized Patients. Journal of Allergy and Clinical Immunology. 2014;133(3):790-796.
4. Joint Task Force on Practice Parameters. Drug Allergy: An Updated Practice Parameter. Annals of Allergy, Asthma & Immunology. 2010;105(4):259-273.

Read this lecture as Markdown